Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.38 EUR | -4.06% | -3.59% | -27.76% |
May. 13 | COMPUGROUP MEDICAL : Reduced to Neutral by Deutsche Bank | ZD |
May. 09 | Berenberg rates Compugroup at 'Buy' - Target 46 euros | DP |
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company is in debt and has limited leeway for investment
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-27.76% | 1.61B | C+ | ||
+17.70% | 342B | B- | ||
+30.03% | 225B | B+ | ||
+7.31% | 158B | B | ||
+13.30% | 57.49B | D+ | ||
+16.25% | 33.77B | C+ | ||
+2.47% | 31.23B | B+ | ||
+144.46% | 29.21B | D+ | ||
+32.71% | 21.97B | B- | ||
+38.99% | 14.81B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- COP Stock
- Ratings CompuGroup Medical SE & Co. KGaA